Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Leave us alone on healthcare service provision, UK tells EC:

This article was originally published in Clinica

Executive Summary

There are growing concerns about the way in which the proposed EU Services Directive could impact healthcare provision at the national level. In the UK, the British Medical Association is calling for healthcare to be excluded from the scope of the Directive as it fears that there could otherwise be a lowering of standards among doctors in the UK and too much of a business orientation in the provision of healthcare. It is said to have the support of UK government ministers and of governments in other countries too. Although the European Commission claims that it does not intend to tell countries how to run their health services, it is proposing under the Directive that member states would need to justify any proposed changes to their health service rules, and prove them to be "non-discriminatory, necessary or proportional." The BMA is to lobby MEPs on this issue ahead of a public hearing on the proposed Directive, scheduled for November 11 in Brussels.

You may also be interested in...

QUOTED. 7 April 2020. Surendar Magar.

California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.

EMA's Decision On Ranitidine Remaining Available Could Come At End Of April

Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.

Perrigo Has Approval For Copy Of OTC Voltaren Arthritis Relief Before GSK Launches The Brand

Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts